DataMeds AI signs nonbinding deal to license and acquire healthcare IP
MEDS•DataMeds AI entered a nonbinding agreement to acquire and license healthcare intellectual property, including patents from EOS and Scilex and expanded exclusive licenses from Datavault AI and Data Health Partners. Closing is targeted for the fourth quarter of 2026, subject to definitive agreements, due diligence and Nasdaq requirements.
1. Proposed IP deal
DataMeds AI entered a nonbinding agreement dated October 19, 2026, to acquire and license healthcare intellectual property. Proposed acquisitions include EOS and Scilex patents for biometric medication delivery verification and wearable-based monitoring of drug effects. Expanded exclusive licenses from Datavault AI and Data Health Partners would support healthcare data management and patient-outcome tracking. Closing is targeted for the fourth quarter of 2026, subject to definitive agreements, due diligence and Nasdaq requirements.
